Physician profile
Jon Mark Macnaughton
NPI 1366485179
$7,698.43
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,478 · 2020: $88.83 · 2021: $257 · 2022: $3,063 · 2023: $764 · 2024: $46.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $4,138.98 | 2019-2023 | Bone Anchors With Arthroscopic Delivery System |
| Medical Device Business Services, INC. | $1,483.46 | 2019 | |
| Zimmer Biomet Holdings, INC. | $1,226.76 | 2022-2023 | Tapestry |
| Amgen INC. | $410.50 | 2020-2023 | Evenity, Prolia |
| Kci USA, INC. | $124.65 | 2019 | |
| Stryker Corporation | $81.33 | 2019 | |
| Abbvie INC. | $78.82 | 2023-2024 | |
| Depuy Synthes Sales INC. | $35.09 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.00 | 2023 | |
| Convatec INC. | $23.39 | 2020 | |
| Acera Surgical, INC. | $21.58 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.02 | 2022 | |
| Sanara Medtech INC. | $13.63 | 2023 | Celleraterx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Macnaughton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.